EPRX — Eupraxia Pharmaceuticals Balance Sheet
0.000.00%
- CA$124.68m
- CA$86.67m
Annual balance sheet for Eupraxia Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | fx Final | fx Final | fx Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 0.89 | 0.118 | 23.7 | 18.3 | 19.3 |
Net Total Receivables | 1.04 | 0.488 | 0.34 | 0.09 | 0.191 |
Prepaid Expenses | |||||
Total Current Assets | 2.03 | 0.894 | 24.2 | 18.6 | 19.8 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.498 | 0.248 | 0.466 | 0.531 | 0.456 |
Other Long Term Assets | |||||
Total Assets | 2.53 | 1.14 | 24.7 | 19.1 | 20.3 |
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 15.9 | 17.7 | 1.79 | 3.06 | 19.4 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Liabilities | 16.2 | 17.8 | 8.58 | 11.3 | 18.1 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | -13.6 | -16.7 | 16.1 | 7.79 | 2.22 |
Total Liabilities & Shareholders' Equity | 2.53 | 1.14 | 24.7 | 19.1 | 20.3 |
Total Common Shares Outstanding |